Article

BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAFi/ErbB1 inhibitors

2020-01-29

Abstract excerpt

<title>Abstract</title> <p>Background: Colorectal cancer (CRC) is a heterogeneous disease with a complex biology and a wide number of altered genes such as BRAF, KRAS and PIK3CA. Advances with new-targeted therapies have been achieved and available treating options have prolonged patient’s survival. However, BRAF-mutated CRC patients remain unresponsive to available therapies with RAF inhibitors (RAFi) alone or c...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 943439d5-d5d4-588d-ac10-1057c1be10d9
DOI: 10.21203/rs.2.15911/v4

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAFi/ErbB1 inhibitorsDOI 10.21203/rs.2.15911/v4Read

BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAF/ErbB inhibitors.Semantic proximity Read

Beyond EGFR inhibitors in advanced colorectal cancer: Targeting BRAF and HER2.Semantic proximity Read

Proliferation of colorectal cancer is promoted by two signaling transduction expression patterns: ErbB2/ErbB3/AKT and MET/ErbB3/MAPK.Semantic proximity Read

Activated MKK3/MYC crosstalk impairs dabrafenib response in BRAFV600E colorectal cancer leading to resistanceSemantic proximity Read

A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction.Semantic proximity Read

The Emerging Role of NRAS Mutations in Colorectal Cancer Patients Selected for Anti-EGFR Therapies.Semantic proximity Read

Genomic landscape and clinical characteristics of ERBB2/HER2-mutated colorectal cancers.Semantic proximity Read

ERBB2 emerges as a new target for colorectal cancer.Semantic proximity Read

ERBB2 deficiency enhances colorectal cancer progression through EGFR-dependent compensatory mechanismsSemantic proximity Read

HER2 in Colorectal Carcinoma: Are We There yet?Semantic proximity Read

Treatment of extended RAS/BRAF wild-type metastatic colorectal cancer with anti-EGFR antibody combinations.Semantic proximity Read

An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapySemantic proximity Read